Radium-223 in Patients With Hormone Refractory Prostate Cancer (HRPC) and Skeletal Metastases
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | April 24, 2008 | ||||
Last Updated Date | June 8, 2011 | ||||
Start Date ICMJE | July 2007 | ||||
Primary Completion Date | February 2008 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE |
Radiation Dosimetry: • Estimation of whole-body retention • Estimation of organ uptake/retention • Estimate retention in blood • Estimation of elimination • Calc. of estimated absorbed radiation dose to target organs. • Pharmacokinetics | ||||
Change History | Complete list of historical versions of study NCT00667537 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
|
||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Radium-223 in Patients With Hormone Refractory Prostate Cancer (HRPC) and Skeletal Metastases | ||||
Official Title ICMJE | A Phase I Open-label, Dosimetry, Biodistribution and Pharmacokinetic Study of Alpharadin™ in Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases | ||||
Brief Summary | The purpose of this study is to evaluate the biodistribution, radiation dosimetry, pharmacokinetics and safety of the investigational radioisotope Radium-223, Alpharadin, in men with prostate cancer and bone metastases that no longer respond to hormonal treatment |
||||
Detailed Description | This is an open-label, biodistribution, radiation dosimetry, pharmacokinetic, safety and efficacy study of Alpharadin treatment. The treatment consists of at least two intravenous administrations of Alpharadin. The target population is patients with asymptomatic or symptomatic (e.g. bone pain) hormone refractory prostate cancer, with documented skeletal metastases. The study is designed to investigate safety, biodistribution, radiation dosimetry and pharmacokinetics of two separate IV administrations of Alpharadin (100 kBq/kg b.w.) separated by six weeks. Furthermore, the secondary objectives of the study are:
|
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 1 | ||||
Study Design ICMJE | Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Drug: Alpharadin TM (Radium-223)
IV administrations of 100 kBq/kg b.w. Two administrations will take place with an interval of 6 weeks. |
||||
Study Arm (s) | 1
Intervention: Drug: Alpharadin TM (Radium-223) |
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Enrollment ICMJE | 6 | ||||
Completion Date | December 2009 | ||||
Primary Completion Date | February 2008 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Male | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United Kingdom | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00667537 | ||||
Other Study ID Numbers ICMJE | BC1-05 | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Gillies O'Bryan-Tear, CMO, Algeta ASA | ||||
Study Sponsor ICMJE | Algeta ASA | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Algeta ASA | ||||
Verification Date | June 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |